- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00615810
ROCKET I - Randomized Open Label Switch for Cholesterol Elevation on Kivexa Evaluation Trial (ROCKET I)
A Phase 4, Open Label, Randomized, Controlled Study to Assess the Effect on Lipid Profile of Switching From a Stable HAART Regimen of Fixed Dose Abacavir/Lamivudine (Kivexa) Plus Efavirenz, to Once Daily Atripla in Adult HIV-1 Infected Subjects With Raised Cholesterol
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
This protocol is a Phase 4, open label, randomized, UK multi-center, controlled study to assess the effect on lipid profile of switching from a stable HAART regimen of Kivexa + EFV to once daily Atripla in adult HIV 1 infected subjects with raised cholesterol.
At Baseline, subjects will be randomized 1:1 to one of two treatment groups:
Treatment Group 1: switch to Atripla Treatment Group 2: Continuation of previous stable HAART regimen of Kivexa + EFV Initiation of treatment with study drugs must take place within 24 hours after Baseline visit. At Week 12, subjects in Treatment Group 2 (continuation of Kivexa and EFV regimen) will switch to Atripla. Treatment in both groups will continue through Week 24
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 4
Kontakter och platser
Studieorter
-
-
Abington
-
Granta Park, Cambridge, Abington, Storbritannien, CB21 6GT
- Gilead Sciences
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Equal to or greater to 18 years old
- Plasma HIV RNA less than 50 copies/mL equal to or greater than 12 weeks prior to Screening
- Stable HAART regimen of Kivexa + EFV for equal to or greater than 24 weeks prior to Screening
- Documented confirmed raised total cholesterol greater than or equal to 5.2 mmol/L for last two consecutive tests (at least 4 weeks apart) with the last result less than or equal to 4 weeks prior to Screening
- Subject willing to continue current unmodified HAART for 12 weeks if randomized to Group 2
- Subjects requiring concomitant lipid regulating therapy must be established on a stable dose/frequency greater than or equal to 12 weeks prior to Screening and be expected to remain stable in dose and frequency throughout the treatment phase of the study
- Adequate renal function by calculated creatinine clearance greater than or equal to 60 mL/min according to the Cockcroft Gault formula
- Negative serum pregnancy test (females of childbearing potential only i.e., not surgically sterile or at least 2 years post-menopausal)
- Hepatic Total Bilirubin ≤ 1.5 mg/dL
- Adequate haematologic function of absolute neutrophil count ≥ 1000/mm3, platelets ≥ 25,000/mm3, Haemoglobin ≥ 8.0g/dL
- Women of childbearing potential (WOCBP) must be using two methods of contraception to avoid pregnancy throughout the study and for up to 12 weeks after the last dose of study drugs in such a manner that the risk of pregnancy is minimized. Subjects may choose two (barrier plus highly effective method - see section 7.8 for further discussion) of the birth control methods listed below:
- Hormonal birth control drugs
- Male or female condoms with or without spermicidal gels
- Diaphragm cervical cap with or without spermicidal gels
- Intrauterine device
- Female subjects who utilize hormone contraceptive as one of their birth control methods must have used the same methods for at least 3 months prior to study dosing
- Female subjects who are postmenopausal for less than 2 years are required to have FSH greater or equal to 40 mIU/mL. If the FSH is less than 40 mIU/mL, the subject must agree to use highly effective method of birth control (as described above) to participate in the study
- Male subjects who are sexually active must be willing to use effective barrier contraception (e.g. condom with spermicide) during heterosexual intercourse from screening through completion of the study and continuing for up to 12 weeks after the last dose of study drugs
- Life expectancy greater to or equal to 1 year
- The ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures
Exclusion Criteria:
- Pregnant or lactating subjects
- Previous treatment with emtricitabine (FTC), tenofovir DF (TDF) or adefovir dipivoxil (ADV)
- Known hypersensitivity to emtricitabine (FTC), tenofovir DF (TDF), efavirenz (EFV) or Truvada
- Documented resistance to any of the study drugs (either genotypic or phenotypic)
- Severe hepatic impairment
- Hepatic transaminases (AST and ALT) greater or equal to 5 times the upper limit of normal (ULN)
- Subjects receiving ongoing therapy with any of the medications that are contraindicated with any of the study drugs. Administration of any of these medications must be discontinued at least 30 days prior to the Baseline visit and for the duration of the study period. The full list of disallowed medications can be found in appendix 7.
- Active, serious infections (other than HIV infection) requiring parenteral antibiotic therapy within 15 days prior to screening
- Prior history of significant renal or bone disease
- Any current known clinical or symptomatic laboratory parameter of GSI grade 4. Asymptomatic grade 4 abnormalities will be permitted at the discretion of the Investigator if deemed clinically appropriate (excluding AEs and laboratory parameters mentioned elsewhere in the inclusion/exclusion criteria). Abnormalities deemed insignificant by the Investigator must be discussed with the Sponsor prior to enrollment.
- Malignancy other than cutaneous Kaposi sarcoma (KS) or basal cell carcinoma. Subjects with biopsy-confirmed cutaneous KS are eligible, but must not have received any systemic therapy for KS within 30 days of baseline and are not anticipated to require systemic therapy during the study
- Current alcohol or substance use judged by the investigator to potentially interfere with subject study compliance
- Subjects currently taking part in any other clinical trial using an investigational product, with the exception of studies where the treatment studied has been stopped for more than 1 month
- Any other clinical condition or prior therapy that, in the opinion of the investigator, would make the subject unsuitable for the study or unable to comply with the dosing requirements
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Aktiv komparator: 2
Open label Kivexa (abacavir (as sulfate) 600 mg/lamivudine 300 mg) once daily for oral administration plus Sustiva (efavirenz 600 mg) once daily for oral administration
|
Open label once daily for oral administration
|
Experimentell: 1
Open label Atripla (efavirenz 600 mg/emtricitabine 200 mg/tenofovir DF 300 mg) once daily for oral administration to be taken on an empty stomach
|
Open label once daily for oral administration to be taken on an empty stomach
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
Change from baseline in total fasting cholesterol at Week 12.
Tidsram: 12 Weeks
|
12 Weeks
|
Sekundära resultatmått
Resultatmått |
Tidsram |
---|---|
Change in total fasting cholesterol at Week 24
Tidsram: 24 fweeks
|
24 fweeks
|
Changes in fasting LDL, HDL, triglycerides, non-HDL cholesterol and cholesterol ratios
Tidsram: 24 weeks
|
24 weeks
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: Cham Herath, Gilead Sciences
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- RNA-virusinfektioner
- Virussjukdomar
- Infektioner
- Blodburna infektioner
- Smittsamma sjukdomar
- Sexuellt överförbara sjukdomar, virala
- Sexuellt överförbara sjukdomar
- Lentivirusinfektioner
- Retroviridae-infektioner
- Immunologiska bristsyndrom
- Immunsystemets sjukdomar
- HIV-infektioner
- Molekylära mekanismer för farmakologisk verkan
- Anti-infektionsmedel
- Antivirala medel
- Omvända transkriptashämmare
- Nukleinsyrasynteshämmare
- Enzyminhibitorer
- Anti-HIV-medel
- Antiretrovirala medel
- Cytokrom P-450 enzymhämmare
- Cytokrom P-450 enzyminducerare
- Cytokrom P-450 CYP3A-inducerare
- Cytokrom P-450 CYP2B6-inducerare
- Cytokrom P-450 CYP2C9-hämmare
- Cytokrom P-450 CYP2C19-hämmare
- Efavirenz
- Efavirenz, Emtricitabin, Tenofovir Disoproxil Fumarate Läkemedelskombination
Andra studie-ID-nummer
- GS-UK-177-0109
- 2007-003354-28 EudraCT Number
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på HIV-infektioner
-
Institut PasteurRekrytering
-
Duke UniversityAvslutadCentral Line-associated Bloodstream Infection (CLABSI)Förenta staterna
-
Catholic University of the Sacred HeartAvslutadCentral Line-associated Bloodstream Infection (CLABSI)
-
The University of Texas Health Science Center,...EurofinsAvslutadOdontogen Deep Space Neck InfectionFörenta staterna
-
Princess Maxima Center for Pediatric OncologyUMC Utrecht; Dutch Cancer SocietyRekryteringCentral Line-associated Bloodstream Infection (CLABSI)Nederländerna
-
University of MalayaTeleflexRekryteringCLABSI - Central Line Associated Bloodstream InfectionMalaysia
-
Johns Hopkins UniversityAvslutadCLABSI - Central Line Associated Bloodstream InfectionFörenta staterna
-
National Taiwan University Hospital Hsin-Chu BranchAvslutadCentral Line-associated Bloodstream Infection (CLABSI)
-
National Taiwan University HospitalAvslutadCentral Line-associated Bloodstream Infection (CLABSI)Taiwan
-
Boston Children's HospitalSterileCare Inc.Anmälan via inbjudanCentral Line komplikation | Central Line-associated Bloodstream Infection (CLABSI)Förenta staterna
Kliniska prövningar på Kivexa plus Sustiva
-
The University of Tennessee, KnoxvilleNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) och andra samarbetspartnersAvslutadFetma | BarnfetmaFörenta staterna
-
ResMedAvslutad
-
Ethicon, Inc.Avslutad
-
Alma Lasers Inc.Okänd
-
University of TrierGerman Research FoundationAvslutadFeedback, PsykologiskTyskland
-
Farmaceutici Damor SpaRekryteringSår och skador | Sårinfektion | SårläkningItalien
-
Johns Hopkins UniversityNational Institute on Aging (NIA); University of MinnesotaRekrytering
-
National Institute of Diabetes and Digestive and...Avslutad
-
University of Sao PauloFundação de Amparo à Pesquisa do Estado de São Paulo; Conselho Nacional...Avslutad
-
Zhejiang Cancer HospitalRekryteringGallgångsadenokarcinomKina